Cite
HARVARD Citation
Doi, T. et al. (2022). A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors. Cancer science. 113 (3), pp. 1010-1017. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Doi, T. et al. (2022). A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors. Cancer science. 113 (3), pp. 1010-1017. [Online].